anti-CD44 mAb (MAT Biopharma)

N/A

Report date: 2025/01/26 18:41:07

Base Information

Drug Nameanti-CD44 mAb (MAT Biopharma)

Drug Alias NameHyaloxanacute myeloid leukemia therapy (MAT Biopharma)anti-CD44 monoclonal antibody (MAT Biopharma)AML therapy (MAT Biopharma)acute myeloid leukemia (MAT Biopharma) +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionCD44 antigen inhibitors

TargetsCD44 antigen

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInstitut National De La Sante Et De La Recherche Medicale

China Registration ClassN/A

Develop Information

Active CompaniesMablife

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A